Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) is expected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Bionano Genomics to post earnings of ($0.81) per share and revenue of $7.88 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

Bionano Genomics Trading Down 0.9%

BNGO opened at $1.12 on Friday. The stock has a market capitalization of $11.40 million, a PE ratio of -0.24 and a beta of 1.69. The firm’s fifty day moving average price is $1.34 and its 200 day moving average price is $1.89. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.12 and a quick ratio of 1.82. Bionano Genomics has a 12-month low of $1.06 and a 12-month high of $5.50.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BNGO shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price (down from $11.00) on shares of Bionano Genomics in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Bionano Genomics in the fourth quarter worth $34,000. Renaissance Technologies LLC acquired a new position in shares of Bionano Genomics during the fourth quarter valued at $57,000. Carret Asset Management LLC raised its stake in shares of Bionano Genomics by 76.4% during the fourth quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Bionano Genomics by 148.8% during the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in Bionano Genomics in the fourth quarter worth about $258,000. Institutional investors and hedge funds own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.